Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]
News [7834]
Articles [63]
Editorials [9]
Conferences [210]
elearning [49]
IO-108 shows promising results in the treatment of advanced relapsed or...
Dr Matthew Taylor - Providence Cancer Institute, Portland, USA
IO-108 shows promising results in the treatment of advanced relapsed or refractory solid tumours ( Dr Matthew Taylor - Providence Cancer Institute, Portland, USA )
20 Apr 2023
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer ( Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA )
17 Apr 2023
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...
Prof Nicolas Girard - Institut Curie, Paris, France
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
11 Apr 2023
Four chemo cycles given with durvalumab and tremelimumab optimise response and...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
LUMINANCE: Results support use of durvalumab and platinum-etoposide for...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...
Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )
6 Apr 2023
Latest treatments in oesophageal cancer
Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA
Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )
5 Apr 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Dr Roger Li - Moffitt Cancer Center, Tampa, USA
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )
22 Mar 2023
African oncologists interaction with pharmaceutical industry
Prof Nazik Hammad - Queen's University, Kingston, Canada
African oncologists interaction with pharmaceutical industry ( Prof Nazik Hammad - Queen's University, Kingston, Canada )
22 Mar 2023
ASCO GU 2023: Prostate QoL data and apalutamide plus active surveillance
Prof Heather Payne and Dr Jochen Walz
ASCO GU 2023: Prostate QoL data and apalutamide plus active surveillance ( Prof Heather Payne and Dr Jochen Walz )
21 Mar 2023
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...
Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )
16 Mar 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation